As people grow older, their risk of developing heart disease increases, and one of the biggest risk factors is obesity. Being ...

This clinical trial is studying an investigational drug for people with obesity/overweight and weight-related conditions. We’re searching for adult men aged 18+ years, with a BMI of 27+ and who are ...

More than half of adults with overweight or obesity prescribed a GLP-1 discontinue their drug within 1 year, with discontinuation rates higher for those without type 2 diabetes, researchers reported ...

Researchers identify a significant association between sugar-sweetened beverage tax and BMI changes among adults living in ...

In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...